If You Invested in Amplia Therapeutics Ltd (INNMF)

Amplia Therapeutics Limited (OTCQB: INNMF; ASX: ATX) is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. According to company disclosures, FAK is described as an increasingly important target in the field of cancer, and Amplia concentrates particularly on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases where fibrosis plays a role, including idiopathic pulmonary fibrosis (IPF).

Amplia’s lead clinical program is the ACCENT trial, a Phase 2a study in metastatic pancreatic cancer. This trial assesses the efficacy of Amplia’s FAK inhibitor narmafotinib (AMP945) in combination with standard chemotherapies gemcitabine and nab-paclitaxel (Abraxane) in first-line patients with advanced pancreatic cancer. Company announcements state that the trial has achieved its primary endpoint, reporting a confirmed objective response rate (ORR) of 35% in one update and 33% in another, compared with 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone. Interim median progression-free survival (PFS) of around 7.6–7.7 months has also been reported in these updates.

Amplia describes narmafotinib as its best-in-class inhibitor of the protein FAK, which is reported to be over-expressed in pancreatic cancer and to be a drug target gaining increasing attention for its role in solid tumors. The company reports that narmafotinib is a highly potent and selective FAK inhibitor and has shown promising data in a range of preclinical cancer studies. In clinical settings, Amplia states that narmafotinib in combination with chemotherapy has continued to be well tolerated, with an adverse effect profile similar to chemotherapy alone, based on interim data from the ACCENT trial.

Beyond ACCENT, Amplia has opened a second clinical study called AMPLICITY. According to the company, this trial is being run under an Investigational New Drug (IND) application at sites in Australia and the United States, and investigates the combination of narmafotinib with the chemotherapy regimen FOLFIRINOX in patients with advanced pancreatic cancer. This indicates that Amplia is exploring narmafotinib across multiple standard-of-care chemotherapy backbones in pancreatic cancer.

Amplia also reports preclinical research collaborations aimed at expanding the potential applications of its FAK inhibitors. In particular, the company has entered a second phase of collaboration with Korean preclinical drug screening company Next & Bio, a subsidiary of Hk Kolmar Holdings in Seoul, Korea. This collaboration examines the activity of Amplia’s FAK inhibitors, including narmafotinib, on patient-derived pancreatic cancer cells that possess mutations in the kRAS gene, which the company notes are known to be present in more than 90% of pancreatic cancers. The next phase of the collaboration is described as investigating combinations of narmafotinib with experimental mutant kRAS inhibitors.

According to Amplia, Next & Bio provides advanced drug screening by testing treatments on cancer cells taken directly from patients, using patient-derived cell models specifically developed for pancreatic cancer. These cells are grown to closely replicate the tumour environment, which the companies state is intended to provide more accurate and predictive preclinical results. Amplia has indicated that initial collaboration data showed activity of its FAK inhibitors on these models and that further work will explore potential synergy between FAK inhibition and kRAS inhibition.

On the intellectual property front, Amplia has announced that it received a Certificate of Grant from the U.S. Patent and Trademark Office for a key patent titled “A salt and crystal form of a FAK Inhibitor,” covering the specific form of narmafotinib being developed clinically. The company reports that this patent has also been granted in regions including Europe, Japan, India, Korea and Australia, and that it extends protection for narmafotinib to at least 2040 in those jurisdictions, with protection in other regions under review by local patent offices.

Amplia repeatedly describes itself as an Australian pharmaceutical company with a pipeline of FAK inhibitors for cancer and fibrosis, a focus on fibrotic cancers such as pancreatic and ovarian cancer, and an interest in chronic fibrotic diseases like IPF. Its public communications emphasize the clinical development of narmafotinib, the progress of the ACCENT and AMPLICITY trials in advanced pancreatic cancer, and the strengthening of its patent position for narmafotinib across multiple major pharmaceutical markets.

Business focus and therapeutic areas

Based on the company’s own descriptions, Amplia’s business focus can be summarized as:

• Developing FAK inhibitors for oncology and fibrotic indications.
• Concentrating development efforts on fibrotic cancers, notably pancreatic and ovarian cancer.
• Exploring the role of FAK inhibition in chronic fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).
• Advancing narmafotinib (AMP945) through clinical trials in advanced pancreatic cancer, in combination with established chemotherapy regimens.
• Supporting its clinical programs with preclinical collaborations that use patient-derived cancer models and explore drug combinations, including with kRAS inhibitors.

Key programs and collaborations

From the available information, Amplia highlights several core programs and partnerships:

• ACCENT trial: A Phase 2a trial in metastatic pancreatic cancer, combining narmafotinib with gemcitabine and nab-paclitaxel (Abraxane) in first-line advanced pancreatic cancer patients. Company updates report confirmed response rates above those seen in the benchmark MPACT study for chemotherapy alone and interim progression-free survival data.
• AMPLICITY trial: A clinical trial conducted under an IND at sites in Australia and the United States, evaluating narmafotinib with FOLFIRINOX in advanced pancreatic cancer.
• Next & Bio collaboration: A preclinical research collaboration with a Korean specialist drug screening company, using patient-derived pancreatic cancer cell models with kRAS mutations to study FAK inhibitors alone and in combination with mutant kRAS inhibitors.
• Patent portfolio for narmafotinib: A granted U.S. patent and patents in multiple other jurisdictions covering the salt and crystal form of narmafotinib being developed clinically, with protection reported to extend to at least 2040 in those regions.

Role of FAK in Amplia’s strategy

Amplia’s disclosures consistently emphasize Focal Adhesion Kinase as central to its scientific and clinical strategy. The company states that FAK is an increasingly important target in oncology, that it is over-expressed in pancreatic cancer, and that it plays a significant role in a number of chronic diseases such as IPF. Narmafotinib is described as a highly potent and selective inhibitor of FAK, and Amplia’s pipeline is framed around exploiting this mechanism in cancer and fibrotic disease settings.

Frequently Asked Questions about Amplia Therapeutics (INNMF)

The following FAQs summarize information drawn directly from company announcements.